At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phentolamine Mesylate as a Reversal of Local Anesthesics
In Brief
A clinical study evaluating Phentolamine Mesylate 0.235 MG/ML [OraVerse] for Anesthesia, Local. Completed, enrolled 90 participants.
Detailed Summary
Oraverse © (Phentolamine mesylate) is a product designed to reverse the effect of local anesthetics used in dentistry. Its main objective is to reduce the postoperative period during which the patient suffers from the lack of sensitivity in the perioral soft tissues, it is an obvious discomfort, a difficulty to speak or eat, and sometimes a risk of self-injury in the lips and / or tongue . The product was approved by the FDA in 2008 although the introduction in Spain has not occurred until December 2015. There are numerous studies that support its use, its effectiveness and safety, although none of the Spanish population, who have not yet had the opportunity to experience it.
Study Details
Timeline
Interventions
compare effect of phentolamine mesylate in three arms